Johnson & Johnson’s (J&J) anti-inflammatory Icotyde (icotrokinra) has secured FDA approval, marking the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis and signaling a potential shift in first-line systemic treatment options.
The once-daily therapy is indicated for adults and adolescents aged 12 years and older who are candidates for systemic therapy or phototherapy. Unlike existing biologics that require injections, Icotyde offers an oral alternative designed to deliver biologic-like efficacy while improving convenience and patient adherence.
Psoriasis affects more than 8 million people in the US, with moderate-to-severe disease often requiring systemic treatment when topical therapies fail. The introduction of an oral IL-23-targeting therapy aligns with evolving treatment goals focused on achieving near-complete skin clearance while minimizing treatment burden.
Icotrokinra works by selectively blocking the interleukin-23 (IL-23) receptor, a key driver of inflammatory pathways involved in psoriasis. By targeting this pathway with a peptide-based oral approach, the therapy represents a new modality in immunology, combining the precision of biologics with the accessibility of oral small molecules.
Related: BMS’ Sotyktu Receives FDA Expansion in Psoriatic Arthritis
The approval is supported by data from four Phase III studies that are a part of the ICONIC clinical program. The drug was evaluated in approximately 2,500 patients, which included both adults and adolescents at the same time, and head-to-head studies. High-impact sites such as the scalp and genitals were assessed.
Results demonstrated high levels of skin clearance, with about 70% of patients achieving clear or almost clear skin at 16 and 24 weeks and more than half reaching PASI 90 responses, benchmarks typically associated with injectable biologics. The benefits were sustained through Week 52.
In head-to-head and comparator analyses, icotrokinra also showed superiority over Bristol Myers Squibb’s TYK2 inhibitor Sotyktu (deucravacitinib), placing it in competitive positioning in a crowded psoriasis market.
Icotyde enters a multibillion-dollar landscape currently dominated by injectable biologics such as AbbVie’s Skyrizi and J&J’s Tremfya. Analysts suggest the drug could disrupt the treatment paradigm by offering comparable efficacy without injections, with forecasts pointing to blockbuster potential exceeding $8 billion in peak annual sales.
“With the FDA approval of Icotyde, Johnson & Johnson is setting a new standard for the treatment of moderate-to-severe plaque psoriasis,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “We’re proud to bring this game-changing innovation to the market, marking a transformative shift in plaque psoriasis management that empowers patients and clinicians to reach their treatment goals.”
Beyond psoriasis, icotrokinra is being evaluated in additional immune-mediated conditions, including psoriatic arthritis and inflammatory bowel diseases.
With the approval, J&J is positioning Icotyde as a first-line systemic option, potentially redefining expectations for both patients and clinicians in the management of plaque psoriasis.
Join or login to leave a comment
JOIN LOGIN